Standard BioTools Inc. filings document the regulatory record for a life-science research tools company centered on mass cytometry, microfluidics, genomics, single-cell proteomics and spatial proteomics. Current reports cover operating results, revenue outlook disclosures, restructuring and cost-savings actions, capital-structure changes, material agreements and risk factors tied to its research-use instrument, consumable and service portfolio.
Proxy materials describe board elections, executive compensation votes, auditor ratification, equity incentive plan approvals and employee stock purchase plan amendments. Form 8-K filings also record material events such as the completed SomaLogic sale, related financial disclosures, shareholder voting matters and Nasdaq continued-listing compliance notices.
Standard BioTools Inc. reported Q1 2026 results showing modest growth in its core tools business and a large one-time gain from selling its SomaScan proteomics business to Illumina.
Revenue from continuing operations was $21.1 million, up 5% year over year, driven by 35% higher consumables sales, while instrument revenue fell 33%. The company posted a net loss from continuing operations of $14.6 million but overall net income of $127.1 million due to a $172.3 million pre-tax gain on the SomaScan sale, recorded in discontinued operations.
Cash, cash equivalents and investments rose to about $526.5 million, reflecting $363.2 million of cash proceeds from the divestiture plus a $25.0 million contingent receivable and potential future earnouts up to $50.0 million. Operating expenses declined 37% as restructuring and prior-year integration efforts reduced R&D and SG&A, though the company continues to incur restructuring charges. The filing also notes a Nasdaq minimum bid-price deficiency notice, creating a risk of future delisting if compliance is not restored.
Standard BioTools Inc. reported first quarter 2026 results with revenue of $21.1 million, up 5% year-over-year, and a sharply reduced operating loss of $12.5 million. Net loss from continuing operations improved to $14.6 million, while adjusted EBITDA loss narrowed to $3.1 million from $14.1 million.
Product trends were mixed: consumables revenue rose 35% to $11.0 million, services grew 5% to $5.7 million, and instruments declined 33% to $4.5 million amid capital-constrained end markets. Operating expenses fell 37% to $23.8 million, reflecting restructuring actions.
The completed sale of SomaLogic drove $141.7 million income from discontinued operations and total net income of $127.1 million. Cash, cash equivalents, restricted cash, and liquid investments reached $523.6 million as of March 31, 2026. The company continues to expect full year 2026 revenue of $80–$85 million.
Standard BioTools Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 17, 2026 at 11:30 a.m. Eastern Time. Proposals include electing three Class I directors, an advisory say‑on‑pay vote, ratifying PwC as auditor, approving a new 2026 Equity Incentive Plan, and adding 1,200,000 shares to the 2017 Employee Stock Purchase Plan.
The proxy highlights a 2025 divestiture of SomaLogic and related units to Illumina for up to $425 million plus 10 years of royalties, with continuing-operations revenue of $85.3 million and $210.7 million in cash and investments as of December 31, 2025, rising to about $550 million after the deal closing in January 2026. It also describes board structure, governance practices, risk oversight, executive compensation philosophy, and strong 2025 say‑on‑pay support of approximately 98.29%.
Standard BioTools Inc. received a notice from Nasdaq that its common stock no longer meets the exchange’s $1.00 minimum bid price requirement after trading below that level for 30 consecutive business days.
The stock continues to trade on the Nasdaq Global Select Market under “LAB” while the company has 180 calendar days, until October 19, 2026, to regain compliance by having a closing bid price at or above $1.00 for at least 10 consecutive business days. If all other listing standards are met, the company may seek an additional 180‑day period by transferring to the Nasdaq Capital Market. Potential remedies mentioned include a reverse stock split. The company intends to work toward restoring compliance but notes there is no assurance it will succeed or receive any extension.
STANDARD BIOTOOLS INC. President & CEO Michael Egholm reported equity compensation activity and related tax withholding transactions. On April 6, 2026, 196,513 restricted stock units converted into the same number of common shares, and 95,014 of those shares were withheld at $0.908 per share to cover tax obligations. Following these events, he directly held 6,695,582 common shares. On March 20, 2026, he also received a grant of 2,345,340 stock options with a $0.9846 exercise price, expiring in 2036, and a separate award of 1,042,373 shares of common stock; both vest in installments over four years.
STANDARD BIOTOOLS INC. reported that SVP & Chief Business Officer Sean Mackay received new equity awards as part of his compensation. He was granted options to buy 612,240 shares of common stock at an exercise price of $0.9846 per share, expiring on March 20, 2036. These options vest over four years, with 1/16 of the underlying shares vesting on May 20, 2026 and the rest in equal quarterly installments, contingent on continued service. He also received 272,107 restricted stock units that follow the same four‑year vesting schedule, each RSU converting into one share of common stock upon vesting. Following the stock grant, his directly held common stock position is 1,032,281 shares.
STANDARD BIOTOOLS INC. Chief Financial Officer Hanjoon Alex Kim reported routine equity compensation activity and related tax withholding. On March 20, 2026, he received 323,173 shares of common stock and a stock option for 727,140 shares at an exercise price of $0.9846, vesting quarterly after May 20, 2026.
On April 6, 2026, 70,183 restricted stock units converted into the same number of common shares. Of these, 21,301 shares were withheld to cover tax obligations from a prior RSU grant, not sold in the market. After these transactions, he directly held 2,779,401 common shares.
Standard BioTools Inc. files its annual report describing a life sciences tools business focused on proteomics and genomics platforms, including CyTOF, Hyperion and Biomark systems. The company sold its SomaScan proteomics subsidiaries to Illumina under a Stock Purchase Agreement signed June 22, 2025, with the transaction closing January 30, 2026, and now reports those operations as discontinued.
For 2025, it highlights a more than $70 billion addressable market in life science research tools and notes that $56.9 million, or 67% of total revenue, came from customers outside the United States. Standard BioTools reports a 2025 net loss of $74.9 million and an accumulated deficit of $1.3 billion as of December 31, 2025, while emphasizing ongoing restructuring and cost actions.
The company details competitive dynamics against major life science tool providers, dependence on key suppliers, extensive global regulatory and data-privacy obligations, and numerous risk factors ranging from market volatility and acquisitions to litigation related to its merger with SomaLogic. As of March 12, 2026, it had 390,071,506 common shares outstanding, 389 employees worldwide, and a non‑affiliate equity market value of approximately $290.9 million as of June 30, 2025.
Casdin Eli reported acquisition or exercise transactions in this Form 4 filing.
STANDARD BIOTOOLS INC. director and 10% owner Eli Casdin received 52,991 restricted stock units on the company’s common stock at $1.17 per share equivalent. The RSUs vest in four equal 25% installments on the last day of the last month of each fiscal quarter of 2026, conditioned on his continued board service. Casdin elected to receive these RSUs instead of $62,000 in cash compensation for board work. After this grant, he directly holds 2,954,053 common shares or equivalents, and investment funds associated with him hold additional indirect positions through Casdin Private Growth Equity Fund II, L.P., Casdin Private Growth Equity Fund, L.P., and Casdin Partners Master Fund, L.P.